Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Importance of tumour mutation burden testing].

Der Pathologe - 1 Dec 2019

Wild Peter J

Abstract excerpt

Although therapy with immune checkpoint inhibitors (ICIs) for patients with non-small-cell lung carcinoma (NSCLC), which has recently become available, does offer a survival advantage compared with chemotherapy, the overall response rate is only around 20 %. Biomarkers are increasingly important in identifying patients who would benefit from ICI therapy. Expression of PD-L1 was the first predictive biomarker to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Microsatellite Instability

Share to Mutation

Share to Tumor Burden

Source

Identifiers

PMID: 31807843
DOI: 10.1007/s00292-019-00717-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Importance of tumour mutation burden testing].PMID 31807843Read ↗

TMB in NSCLC: A Broken Dream?Semantic proximity Read ↗

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity Read ↗

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer.Semantic proximity Read ↗

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read ↗

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read ↗

Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis.Semantic proximity Read ↗

The emerging development of tumor mutational burden in patients with NSCLC.Semantic proximity Read ↗

[Research Progress on Heterogeneity of Tumor Mutation Burden in Patients with Non-small Cell Lung Cancer].Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.